G. Finocchiaro

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
G B Finocchiaro, G Finocchiaro, G. Finocchiaro, Giovanna Finocchiaro
Publication record
100 papers · 4,009 citations · H-index 30

PAPERS

PIK3CA Alterations in NSCLC: Clinical Characteristics of a "Neglected" Population of Oncogene-Addicted Patients.
20260 citationsauthor #4
Management of patients with extensive small-cell lung cancer in the immunotherapy era: an Italian consensus through a Delphi approach.
20243 citationsauthor #11
Response to first-line pembrolizumab in metastatic KRAS-mutated non-small-cell lung cancer.
20241 citationsauthor #3
Retreatment with Immune Checkpoint Inhibitors in the New Scenario of Immunotherapy in Non-Small Cell Lung Cancer
20244 citationsauthor #3
First-line immunotherapy in patients with mNSCLC with rare molecular alterations.
20240 citationsauthor #2
Detection of MET amplification (METamp) in patients with EGFR mutant (m) NSCLC after first-line (1L) osimertinib.
202318 citationsauthor #5
Biomarker-directed, pembrolizumab-based combination therapy in non-small cell lung cancer: phase 2 KEYNOTE-495/KeyImPaCT trial interim results
202335 citationsauthor #12
The Era of Immunotherapy in Small-Cell Lung Cancer: More Shadows Than Light?
20234 citationsauthor #8
635 KEYNOTE-495/KeyImPaCT: updated analysis of a biomarker-directed, randomized, phase 2 trial of pembrolizumab-based combination therapy for non-small cell lung cancer
20221 citationsauthor #12
Current treatment approaches for brain metastases in ALK/ROS1/NTRK-positive non-small-cell lung cancer
20221 citationsauthor #6
OS05.6.A Modification of the tumor microenvironment in patients with glioblastoma using autologous, genetically modified, hematopoietic stem cell-based therapy: the TEM-GBM STUDY (NCT03866109)
20222 citationsauthor #1
284MO Targeting the tumor microenvironment of glioblastoma multiforme using a macrophage-based treatment for the local delivery of immune-therapeutic payload: The TEM-GBM study (NCT03866109)
20223 citationsauthor #1
Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis
202216 citationsauthor #21
LBA52 Tepotinib + osimertinib for EGFRm NSCLC with MET amplification (METamp) after progression on first-line (1L) osimertinib: Initial results from the INSIGHT 2 study
202236 citationsauthor #6
457 KEYNOTE-495/KeyImPaCT: interim analysis of a randomized, biomarker-directed, phase 2 trial of pembrolizumab-based combination therapy for non–small cell lung cancer (NSCLC)
20217 citationsauthor #12
P22.03 Role of Circulating Tumor Cell Subpopulations in Operable Non-Small Cell Lung Cancer Diagnosis and Prognosis
20210 citationsauthor #8
379TiP TEM-GBM: A phase I-IIa clinical study of genetically modified Tie-2-expressing monocytes in patients with glioblastoma multiforme
20211 citationsauthor #1
IMMU-01. TEM-GBM: AN OPEN-LABEL, PHASE I/IIA DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND EFFICACY OF GENETICALLY MODIFIED TIE-2 EXPRESSING MONOCYTES TO DELIVER IFN-A WITHIN GLIOBLASTOMA TUMOR MICROENVIRONMENT
20210 citationsauthor #1
Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC.
20217 citationsauthor #4
Subpopulations of Circulating Cells with Morphological Features of Malignancy Are Preoperatively Detected and Have Differential Prognostic Significance in Non-Small Cell Lung Cancer
20217 citationsauthor #8
Pembrolizumab-Induced Vanishing Bile Duct Syndrome: a Case Report
20218 citationsauthor #4
The use of radiation therapy for oligoprogressive/oligopersistent oncogene-driven non small cell lung cancer: State of the art.
202035 citationsauthor #6
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
2020495 citationsauthor #18
Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancer.
202019 citationsauthor #3
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients Aged ≥ 75 Years With Non-small-cell Lung Cancer (NSCLC): An Italian, Multicenter, Retrospective Study.
202020 citationsauthor #14
Clinical and prognostic implications of sarcopenia in patients affected by locally advanced NSCLC.
20190 citationsauthor #4
Impact of Exon 19 Deletion Subtypes in EGFR‐Mutant Metastatic Non–Small‐Cell Lung Cancer Treated With First‐Line Tyrosine Kinase Inhibitors
201924 citationsauthor #3
Be-TeaM: An Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients.
201910 citationsauthor #8
Nivolumab in disadvantaged subgroups of metastatic non-small-cell lung cancer patients: a single-institution experience.
20191 citationsauthor #2
Liquid Biopsy Testing Can Improve Selection of Advanced Non-Small-Cell Lung Cancer Patients to Rechallenge with Gefitinib
20199 citationsauthor #7
Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
20199 citationsauthor #4
Survival outcome of tyrosine kinase inhibitors beyond progression in association to radiotherapy in oligoprogressive EGFR-mutant non-small-cell lung cancer.
201916 citationsauthor #2
Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
201875 citationsauthor #9
Disadvantaged subgroups of metastatic non-small cell lung cancer (mNSCLC) patients treated with nivolumab.
20180 citationsauthor #2
Checkpoint inhibitors: 'raising the bar' also in brain metastases from non-small-cell lung cancer?
20186 citationsauthor #2
Tumor heterogeneity, hypoxia, and immune markers in surgically resected non-small-cell lung cancer
201821 citationsauthor #8
Neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) as predictive indicators of nivolumab efficacy in metastatic non-small cell lung cancer (mNSCLC).
20180 citationsauthor #3
Clinical outcome of EGFR-mutant NSCLC patients continuing TKIs beyond progression in combination with local ablative radiotherapy.
20170 citationsauthor #2
Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come
201739 citationsauthor #3
P1.06-006 Treatment beyond Progression in Patients with Advanced Squamous NSCLC Participating in the Expanded Access Programme (EAP): Topic: Advanced General
20174 citationsauthor #18
P3.02c-094 Italian Nivolumab Advanced Squamous NSCLC Expanded Access Program: Efficacy and Safety in Patients with Brain Metastases: Topic: IT Clinical
20177 citationsauthor #18
Predictive impact of different exon 19 deletions in EGFR-mutant NSCLC treated with first-line TKIs.
20170 citationsauthor #3
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.
201638 citationsauthor #14
Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Access Programme (EAP) in Italy
201624 citationsauthor #18
Clinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic Patients.
201649 citationsauthor #10
Outcome Evaluation of Oligometastatic Patients Treated with Surgical Resection Followed by Hypofractionated Stereotactic Radiosurgery (HSRS) on the Tumor Bed, for Single, Large Brain Metastases
201623 citationsauthor #9
Long-Term Follow-up Results of the DANTE Trial, a Randomized Study of Lung Cancer Screening with Spiral Computed Tomography.
2015316 citationsauthor #21
Prognostic and predictive value of MET deregulation in non-small cell lung cancer.
201555 citationsauthor #1
Phase II Study of Afatinib, an Irreversible ErbB Family Blocker, in EGFR FISH-Positive Non–Small-Cell Lung Cancer
201528 citationsauthor #2
When is surgery indicated for small-cell lung cancer?
201543 citationsauthor #3
Increased SOX2 Gene Copy Number Is Associated with FGFR1 and PIK3CA Gene Gain in Non-Small Cell Lung Cancer and Predicts Improved Survival in Early Stage Disease
201475 citationsauthor #2
SOX2 and FGFR1 gene copy number in surgically resected non-small cell lung cancer (NSCLC).
20122 citationsauthor #2
TGFb expression as predictor of outcome in EGFR wild type (WT) metastatic non-small cell lung cancer (NSCLC) patients (PTS) treated with EGFR tyrosine kinase inhibitors (TKIs).
20121 citationsauthor #1
Expression of folate pathway regulators and pemetrexed (pem) activity in patients (pts) with advanced non-small cell lung cancer (NSCLC).
20121 citationsauthor #6
9007 ORAL Phase II Study of Afatinib (BIBW 2992), an Irreversible ErbB Family Blocker, in Patients With EGFR FISH-positive Advanced NSCLC
20111 citationsauthor #1
Prognostic role of nitrotyrosines in surgically resected non-small cell lung cancer (NSCLC).
20110 citationsauthor #5
Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients.
201077 citationsauthor #3
Platinum and Pemetrexed Combination in Advanced Solid Tumors
20100 citationsauthor #1
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy.
201042 citationsauthor #11
Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients.
2009547 citationsauthor #12
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.
2009104 citationsauthor #10
Insuline like growth factor receptor-1 (IGFR-1), MET, and BRAF and primary resistance to cetuximab therapy in colorectal cancer patients
20088 citationsauthor #1
EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients: how do we interpret the clinical and biomarker data?
20082 citationsauthor #3
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
2008187 citationsauthor #3
Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
2008187 citationsauthor #4
M1* RESISTANCE TO EGFR TKIS AND SERUM PROTEOMIC PROFILE IN NON SMALL CELL LUNG CANCER (NSCLC) PATIENTS
20080 citationsauthor #17
Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.
2007226 citationsauthor #10
Is gemcitabine cost effective in cancer treatment?
20072 citationsauthor #2
Optimizing Anti-EGFR Strategies in Cancer Treatment
20070 citationsauthor #2
EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer
200782 citationsauthor #1
First-line treatment of non small cell lung cancer
20072 citationsauthor #2
3002 ORAL Comprehensive assessment of molecular markers predicting response to cetuximab therapy in colorectal cancer
20070 citationsauthor #2
EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
200794 citationsauthor #8
Surrogate Predictive Biomarkers for Response to Anti-EGFR Agents: State of the Art and Challenges
20070 citationsauthor #3
EGFR tyrosine kinase inhibitors: a therapy for a few, for the majority or for all non-small cell lung cancer patients?
20072 citationsauthor #1
Surrogate predictive biomarkers for response to anti-EGFR agents: state of the art and challenges.
20077 citationsauthor #3
Clinical experience with gefitinib: an update.
200651 citationsauthor #2
Development of gemcitabine in non-small cell lung cancer: the Italian contribution.
200612 citationsauthor #3
EGFR, HER2, and phospho-Akt are not predictive factors for response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC).
20064 citationsauthor #6
Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib.
200697 citationsauthor #7
Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
200650 citationsauthor #2
Anti-cancer therapy with EGFR inhibitors: factors of prognostic and predictive significance.
200631 citationsauthor #2
Use of molecular screening for clinical trials with EGFR inhibitors
20060 citationsauthor #3
Insulin-like growth factor receptor 1 (IGFR-1) is signiﬁcantly associated with longer survival in non-small-cell lung cancer patients treated with geﬁtinib
20061 citationsauthor #7
Cisplatin and etoposide followed by concurrent chemo-radiation therapy for limited stage small cell lung cancer (SCLC-LS)
20050 citationsauthor #5
Role of gemcitabine in cancer therapy.
2005329 citationsauthor #2
Perspectives on salvage therapy for non-small-cell lung cancer.
20058 citationsauthor #2
L-Carnitine in the Treatment of Mild or Moderate Hepatic Encephalopathy
200358 citationsauthor #5
Study of in vitro and in vivo effects of the piperidine nitroxide Tempol--a potential new therapeutic agent for gliomas.
200344 citationsauthor #5
Levocarnitine Administration in Elderly Subjects with Rapid Muscle Fatigue
200393 citationsauthor #5
Paracrine delivery of IL-12 against intracranial 9L gliosarcoma in rats.
200063 citationsauthor #10
Rare Tendinopathy Associated with Fluoroquinolone Treatment
19990 citationsauthor #2
[Various types of small intestine occlusion. Case contribution].
19920 citationsauthor #1
[The role of the intestine in the pathogenesis and treatment of multiple organ failure].
19890 citationsauthor #2
[Non-epithelial tumors of the stomach. Retrospective analysis of 18 cases].
19820 citationsauthor #6
[Experimental studies on the use of the mechanical suture device in bronchial stump closure].
19821 citationsauthor #4
One case of dwarfism caracterized by high plasma levels of the immunoreactive HGH and low somatomedine activity
19810 citationsauthor #3
[Rare case of chemodectoma with a rare mediastinal location].
19811 citationsauthor #5
[The automatic stapling devices: a real progress in the resections of pulmonary tissue (author's transl)].
19810 citationsauthor #4
[Report of a case of vesico-cervical fistula of obstetrical origin].
19791 citationsauthor #1

TIMELINE

1979 1 citations

1981 1 citations

1982 1 citations

1989 0 citations

1992 0 citations

1999 0 citations

2000 63 citations

2003 195 citations

2005 337 citations

2006 246 citations

2007 415 citations

2008 197 citations

2009 651 citations

2010 119 citations

2011 1 citations

2012 4 citations

2014 75 citations

2015 442 citations

2016 134 citations

2017 50 citations

2018 102 citations

2019 69 citations

2020 569 citations

2021 30 citations

2022 59 citations

2023 57 citations

2024 8 citations

2026 0 citations

G. Finocchiaro

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT